Laurent Peyrin Biroulet (L Peyrin-Biroulet, Laurent Peyrin-Biroulet)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 100

Top Venues

Alimentary pharmacology & therapeutics

United European gastroenterology journal

Nature reviews. Gastroenterology & hepatology

Gut

This page only lists publications with an associated author ORCID identifier.

Publications

Nadia Wespi, Stephan Vavricka, Stephan Brand, Patrick Aepli, Emanuel Burri, Benjamin Misselwitz, Frank Seibold, Petr Hruz, Laurent Peyrin Biroulet, Alain Schoepfer, Luc Biedermann, Christiane Sokollik, Gerhard Rogler, Thomas Greuter
Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey. United European gastroenterology journal (2024)
Léa Sequier, Bénédicte Caron, Damien Loeuille, Sailish Honap, Vipul Jairath, Patrick Netter, Silvio Danese, Jean Sibilia, Laurent Peyrin Biroulet
Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease. Alimentary pharmacology & therapeutics 60 (6) (2024)
Mariangela Allocca, Gaia Catalano, Edoardo V Savarino, Maria Chaparro, Asaf Levartovsky, George Michalopoulos, Nikos Viazis, Fotis S Fousekis, Andreas Psistakis, Daniele Noviello, Catarina Neto do Nascimento, Benedicte Caron, Vassiliki Kitsou, Giorgos Bamias, María José García, Eirini Zacharopoulou, Kalliopi Foteinogiannopoulou, Ferdinando D'Amico, Ioannis Koutroubakis, Pierre Ellul, Maria Tzouvala, Laurent Peyrin Biroulet, Joanna Torres, Flavio Caprioli, Konstantinos Karmiris, Angeliki Theodoropoulou, Konstantinos H Katsanos, Dimitrios K Christodoulou, Gerassimos J Mantzaris, Uri Kopylov, Francisco Javier García-Alonso, Silvio Danese, Fernando Magro, Fornari Carla, Gionata Fiorino
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. United European gastroenterology journal 12 (5) (2024)
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin Biroulet
Navigating the complexities of drug development for inflammatory bowel disease. Nature reviews. Drug discovery 23 (7) (2024)
Bénédicte Caron, Alexandre Habert, Olivier Bonsack, Houda Camara, Elodie Jeanbert, Tommaso Lorenzo Parigi, Patrick Netter, Silvio Danese, Laurent Peyrin Biroulet
Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. United European gastroenterology journal 12 (5) (2024)
Léa Sequier, Bénédicte Caron, Damien Loeuille, Sailish Honap, Vipul Jairath, Patrick Netter, Silvio Danese, Jean Sibilia, Laurent Peyrin Biroulet
Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease. Alimentary pharmacology & therapeutics (2024)
Mariangela Allocca, Gaia Catalano, Edoardo V Savarino, Maria Chaparro, Asaf Levartovsky, George Michalopoulos, Nikos Viazis, Fotis S Fousekis, Andreas Psistakis, Daniele Noviello, Catarina Neto do Nascimento, Benedicte Caron, Vassiliki Kitsou, Giorgos Bamias, María José García, Eirini Zacharopoulou, Kalliopi Foteinogiannopoulou, Ferdinando D'Amico, Ioannis Koutroubakis, Pierre Ellul, Maria Tzouvala, Laurent Peyrin Biroulet, Joanna Torres, Flavio Caprioli, Konstantinos Karmiris, Angeliki Theodoropoulou, Konstantinos H Katsanos, Dimitrios K Christodoulou, Gerassimos J Mantzaris, Uri Kopylov, Francisco Javier García-Alonso, Silvio Danese, Fernando Magro, Fornari Carla, Gionata Fiorino
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. United European gastroenterology journal (2024)
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin Biroulet
Navigating the complexities of drug development for inflammatory bowel disease. Nature reviews. Drug discovery 23 (7) (2024)
Bénédicte Caron, Alexandre Habert, Olivier Bonsack, Houda Camara, Elodie Jeanbert, Tommaso Lorenzo Parigi, Patrick Netter, Silvio Danese, Laurent Peyrin Biroulet
Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. United European gastroenterology journal (2024)
Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V Loftus, Ian L P Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Angela de Haas, Tomasz Masior, Christine Rudolph, Laurent Peyrin Biroulet
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study. Alimentary pharmacology & therapeutics (2024)
Bénédicte Caron, Philippe Seksik, Anthony Buisson, Pauline Wils, Guillaume Savoye, Carmen Stefanescu, David Laharie, Lucas Guillo, Vered Abitbol, Joelle Bonnet, Romain Altwegg, Lucine Vuitton, Driffa Moussata, Arnaud Bourreille, Amélie Biron, Cyrielle Gilletta, Mathurin Fumery, Stephane Nahon, Stéphane Nancey, Houda Camara, Laurent Peyrin Biroulet
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. Therapeutic advances in gastroenterology 17 (2024)
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin Biroulet
Navigating the complexities of drug development for inflammatory bowel disease. Nature reviews. Drug discovery (2024)
Sailish Honap, Vipul Jairath, Bruce E Sands, Parambir S Dulai, Marjorie Costa Argollo, Laurent Peyrin Biroulet
Acute severe ulcerative colitis trials: the past, the present and the future. Gut (2024)
Bénédicte Caron, Philippe Seksik, Anthony Buisson, Pauline Wils, Guillaume Savoye, Carmen Stefanescu, David Laharie, Lucas Guillo, Vered Abitbol, Joelle Bonnet, Romain Altwegg, Lucine Vuitton, Driffa Moussata, Arnaud Bourreille, Amélie Biron, Cyrielle Gilletta, Mathurin Fumery, Stephane Nahon, Stéphane Nancey, Houda Camara, Laurent Peyrin Biroulet
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. Therapeutic advances in gastroenterology 17 (2024)
Bénédicte Caron, Alexandre Habert, Olivier Bonsack, Houda Camara, Elodie Jeanbert, Tommaso Lorenzo Parigi, Patrick Netter, Silvio Danese, Laurent Peyrin Biroulet
Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. United European gastroenterology journal 12 (5) (2024)
Silvio Danese, Laurent Peyrin Biroulet
Are all the IL-23 blockers the same in inflammatory bowel disease? Nature reviews. Gastroenterology & hepatology (2024)
Mariangela Allocca, Gaia Catalano, Edoardo V Savarino, Maria Chaparro, Asaf Levartovsky, George Michalopoulos, Nikos Viazis, Fotis S Fousekis, Andreas Psistakis, Daniele Noviello, Catarina Neto do Nascimento, Benedicte Caron, Vassiliki Kitsou, Giorgos Bamias, María José García, Eirini Zacharopoulou, Kalliopi Foteinogiannopoulou, Ferdinando D'Amico, Ioannis Koutroubakis, Pierre Ellul, Maria Tzouvala, Laurent Peyrin Biroulet, Joanna Torres, Flavio Caprioli, Konstantinos Karmiris, Angeliki Theodoropoulou, Konstantinos H Katsanos, Dimitrios K Christodoulou, Gerassimos J Mantzaris, Uri Kopylov, Francisco Javier García-Alonso, Silvio Danese, Fernando Magro, Fornari Carla, Gionata Fiorino
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. United European gastroenterology journal 12 (5) (2024)
Silvio Danese, Laurent Peyrin Biroulet
Are all the IL-23 blockers the same in inflammatory bowel disease? Nature reviews. Gastroenterology & hepatology 21 (3) (2024)
Bénédicte Caron, Alexandre Habert, Olivier Bonsack, Houda Camara, Elodie Jeanbert, Tommaso Lorenzo Parigi, Patrick Netter, Silvio Danese, Laurent Peyrin Biroulet
Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. United European gastroenterology journal 12 (5) (2024)
Sailish Honap, Nelly Agrinier, Silvio Danese, Laurent Peyrin Biroulet
Disease prevention trials in IBD: feasibility to future outlook. Nature reviews. Gastroenterology & hepatology (2024)
Mariangela Allocca, Gaia Catalano, Edoardo V Savarino, Maria Chaparro, Asaf Levartovsky, George Michalopoulos, Nikos Viazis, Fotis S Fousekis, Andreas Psistakis, Daniele Noviello, Catarina Neto do Nascimento, Benedicte Caron, Vassiliki Kitsou, Giorgos Bamias, María José García, Eirini Zacharopoulou, Kalliopi Foteinogiannopoulou, Ferdinando D'Amico, Ioannis Koutroubakis, Pierre Ellul, Maria Tzouvala, Laurent Peyrin Biroulet, Joanna Torres, Flavio Caprioli, Konstantinos Karmiris, Angeliki Theodoropoulou, Konstantinos H Katsanos, Dimitrios K Christodoulou, Gerassimos J Mantzaris, Uri Kopylov, Francisco Javier García-Alonso, Silvio Danese, Fernando Magro, Fornari Carla, Gionata Fiorino
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. United European gastroenterology journal 12 (5) (2024)
Fábio Vieira Teixeira, Laurent Peyrin Biroulet, Silvio Danese
ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS? Arquivos de gastroenterologia 61 (2024)
Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V Loftus, Ian L P Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Angela de Haas, Tomasz Masior, Christine Rudolph, Laurent Peyrin Biroulet
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study. Alimentary pharmacology & therapeutics 60 (5) (2024)
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin Biroulet
Navigating the complexities of drug development for inflammatory bowel disease. Nature reviews. Drug discovery 23 (7) (2024)
Mariangela Allocca, Gaia Catalano, Edoardo V Savarino, Maria Chaparro, Asaf Levartovsky, George Michalopoulos, Nikos Viazis, Fotis S Fousekis, Andreas Psistakis, Daniele Noviello, Catarina Neto do Nascimento, Benedicte Caron, Vassiliki Kitsou, Giorgos Bamias, María José García, Eirini Zacharopoulou, Kalliopi Foteinogiannopoulou, Ferdinando D'Amico, Ioannis Koutroubakis, Pierre Ellul, Maria Tzouvala, Laurent Peyrin Biroulet, Joanna Torres, Flavio Caprioli, Konstantinos Karmiris, Angeliki Theodoropoulou, Konstantinos H Katsanos, Dimitrios K Christodoulou, Gerassimos J Mantzaris, Uri Kopylov, Francisco Javier García-Alonso, Silvio Danese, Fernando Magro, Fornari Carla, Gionata Fiorino
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. United European gastroenterology journal 12 (5) (2024)
Fernando Magro, Paula Leão Moreira, Gaia Catalano, Catarina Alves, Fernando Magro, Maria Manuela Estevinho, Isabel Silva, Axel U Dignass, Laurent Peyrin Biroulet, Silvio Danese, Vipul Jairath, Claudia Camila Dias, Mafalda Santiago
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis. United European gastroenterology journal (2023)
Luca Massimino, Orazio Palmieri, Amanda Facoetti, Davide Fuggetta, Salvatore Spanò, Luigi Antonio Lamparelli, Silvia D'Alessio, Stefania Cagliani, Federica Furfaro, Ferdinando D'Amico, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Daniele Noviello, Anna Latiano, Fabrizio Bossa, Tiziana Latiano, Alessandra Pirola, Luca Mologni, Rocco Giovanni Piazza, Danilo Abbati, Francesco Perri, Chiara Bonini, Laurent Peyrin Biroulet, Alberto Malesci, Vipul Jairath, Marjorie Costa Argollo, Federica Ungaro
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo . Gut (2023)
Pablo Andres Olivera, Juan S Lasa, Giovanni Peretto, Stephane Zuily, Silvio Danese, Laurent Peyrin Biroulet
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs. Alimentary pharmacology & therapeutics (2023)
Sailish Honap, Laurent Peyrin Biroulet
Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease? Alimentary pharmacology & therapeutics (2023)
Fernando Magro, Maria Manuela Estevinho, Gaia Catalano, Marta Patita, Bruno Arroja, Paula Lago, Isadora Rosa, Helena Tavares Sousa, Paula Ministro, Irina Mocanu, Ana Vieira, Joana Castela, Joana Moleiro, Fernando Magro, Eugénia Cancela, Paula Sousa, Francisco Portela, Luís Correia, Paula Moreira, Mafalda Santiago, Sandra Dias, Joana Afonso, Silvio Danese, Laurent Peyrin Biroulet, Cláudia Camila Dias, null null
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study. United European gastroenterology journal (2023)
Olivier Bonsack, Bénédicte Caron, Cedric Baumann, Anne Charlotte Heba, Sophie Vieujean, Djesia Arnone, Patrick Netter, Silvio Danese, Didier Quilliot, Laurent Peyrin Biroulet
Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic. United European gastroenterology journal (2023)
Mathurin Fumery, Laurent Peyrin Biroulet
Editorial: risankizumab - ready to break ceilings? author's reply. Alimentary pharmacology & therapeutics 57 (8) (2023)
Olga Maria Nardone, Marietta Iacucci, Vincenzo Villanacci, Laurent Peyrin Biroulet, Subrata Ghosh, Silvio Danese, Tommaso Lorenzo Parigi
Real-world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey. United European gastroenterology journal (2023)
Ferdinando D'Amico, Laurent Peyrin Biroulet, Silvio Danese
Disease clearance in ulcerative colitis: Is the ultimate therapeutic target? United European gastroenterology journal (2023)
Geert D'Haens, Laurent Peyrin Biroulet, Daniel J B Marks, Edoardo Lisi, Lia Liefaard, Andrew Beaton, Naren Srinivasan, Gerben Bouma, Naveen Prasad, Raymond Cameron, Zeid Kayali, Ruth Tarzi, Stephen Hanauer, William J Sandborn
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Alimentary pharmacology & therapeutics (2023)
Achuthan Aruljothy, Siddharth Singh, Neeraj Narula, Gordon William Moran, Sudheer K Vuyyuru, Malcolm Hogan, Alexa Zayadi, John K MacDonald, Benedicte Caron, Silvio Danese, Laurent Peyrin Biroulet, Christopher Ma, Vipul Jairath
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis. Alimentary pharmacology & therapeutics (2023)
Laurent Peyrin Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel U Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R Gaya, Silvio Danese
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST. Alimentary pharmacology & therapeutics (2023)
Silvio Danese, Virginia Solitano, Vipul Jairath, Laurent Peyrin Biroulet
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance. Nature reviews. Gastroenterology & hepatology 20 (3) (2023)
Julian Panes, Severine Vermeire, Geert R D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Daniel R Gaya, Laurent Peyrin Biroulet, Axel U Dignass, null null
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial. United European gastroenterology journal (2023)
B Caron, Laurent Peyrin Biroulet
Ulcerative proctitis: Challenges for clinical management. Journal of gastroenterology and hepatology (2023)
Pauline Wils, Vipul Jairath, Bruce E Sands, Fernando Magro, Walter Reinisch, David T Rubin, Silvio Danese, Cédric Baumann, Laurent Peyrin Biroulet
Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European gastroenterology journal (2023)
Bénédicte Caron, Mathurin Fumery, Patrick Netter, Laurent Peyrin Biroulet
Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure. Alimentary pharmacology & therapeutics 55 (4) (2022)
Marjorie Costa Argollo, Virginia Solitano, Vipul Jairath, Laurent Peyrin Biroulet
The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut 71 (12) (2022)
Mathurin Fumery, Antoine Defrance, Xavier Roblin, Romain Altwegg, Benedicte Caron, Xavier Hébuterne, Carmen Stefanescu, Antoine Meyer, Maria Nachury, David Laharie, Stephane Nancey, Catherine Le Berre, Melanie Serrero, Sophie Geyl, Cyrielle Giletta, Philippe Ah-Soune, Nicolas Duveau, Mathieu Uzzan, Vered Abitbol, Amelie Biron, My-Linh Tran-Minh, Thierry Paupard, Lucine Vuitton, Yasmine Elgharabawy, Laurent Peyrin Biroulet
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary pharmacology & therapeutics 57 (4) (2022)
Mathurin Fumery, Antoine Defrance, Xavier Roblin, Romain Altwegg, Benedicte Caron, Xavier Hébuterne, Carmen Stefanescu, Antoine Meyer, Maria Nachury, David Laharie, Stephane Nancey, Catherine Le Berre, Melanie Serrero, Sophie Geyl, Cyrielle Giletta, Philippe Ah-Soune, Nicolas Duveau, Mathieu Uzzan, Vered Abitbol, Amelie Biron, My-Linh Tran-Minh, Thierry Paupard, Lucine Vuitton, Yasmine Elgharabawy, Laurent Peyrin Biroulet
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary pharmacology & therapeutics (2022)
Virginie Millet, Thomas Gensollen, Michael Maltese, Melanie Serrero, Nathalie Lesavre, Christophe Bourges, Christophe Pitaval, Sophie Cadra, Lionel Chasson, Thien Phong Vu Man, Marion Masse, Juan Jose Martinez-Garcia, Fabrice Tranchida, Laetitia Shintu, Konrad Mostert, Erick Strauss, Patricia Lepage, Mathias Chamaillard, Achille Broggi, Laurent Peyrin Biroulet, Jean-Charles Grimaud, Philippe Naquet, Franck Galland
Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis. Gut (2022)
Silvio Danese, Virginia Solitano, Vipul Jairath, Laurent Peyrin Biroulet
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance. Nature reviews. Gastroenterology & hepatology (2022)
Laurent Peyrin Biroulet, Guillaume Bouguen, David Laharie, Gauthier Pellet, Guillaume Savoye, Cyrielle Gilletta, Christophe Michiels, Anthony Buisson, Mathurin Fumery, Jean-Noël Trochu, Patrice Cacoub, null null
Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study. Digestive diseases and sciences 67 (12) (2022)
Mathilde Laland, Marie François, Ferdinando D'Amico, Camille Zallot, Charlène Brochard, Marie Dewitte, Laurent Siproudhis, Laurent Peyrin Biroulet, Guillaume Bouguen
Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn's disease. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2022)
Sophie Vieujean, Ferdinando D'Amico, Patrick Netter, Silvio Danese, Laurent Peyrin Biroulet
Landscape of new drugs and targets in inflammatory bowel disease. United European gastroenterology journal (2022)
Ferdinando D'Amico, Gionata Fiorino, Virginia Solitano, Eugenia Massarini, Lucas Guillo, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Stefanos Bonovas, Fernando Magro, Laurent Peyrin Biroulet, Silvio Danese
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study. United European gastroenterology journal 10 (7) (2022)
Lucas Guillo, Laurent Peyrin Biroulet, Silvio Danese
Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease. Alimentary pharmacology & therapeutics 55 (9) (2022)
Paolo Angelo Cortesi, Gionata Fiorino, Laurent Peyrin Biroulet, Lorenzo Giovanni Mantovani, Vipul Jairath, Kristine Paridaens, Fredrik L Andersson, Silvio Danese
Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis. Alimentary pharmacology & therapeutics (2022)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Kristine Paridaens, Fernando Magro, Silvio Danese, Laurent Peyrin Biroulet
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. United European gastroenterology journal 10 (8) (2022)
Mathurin Fumery, Antoine Defrance, Xavier Roblin, Romain Altwegg, Benedicte Caron, Xavier Hébuterne, Carmen Stefanescu, Antoine Meyer, Maria Nachury, David Laharie, Stephane Nancey, Catherine Le Berre, Melanie Serrero, Sophie Geyl, Cyrielle Giletta, Philippe Ah-Soune, Nicolas Duveau, Mathieu Uzzan, Vered Abitbol, Amelie Biron, My-Linh Tran-Minh, Thierry Paupard, Lucine Vuitton, Yasmine Elgharabawy, Laurent Peyrin Biroulet
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary pharmacology & therapeutics 57 (4) (2022)
Jenny Tannoury, Maria Nachury, Carole Martins, Melanie Serrero, Jerome Filippi, Xavier Roblin, Anne Bourrier, Guillaume Bouguen, Denis Franchimont, Guillaume Savoye, Anthony Buisson, Edouard Louis, Stephane Nancey, Vered Abitbol, Jean-Marie Reimund, Olivier DeWitt, Lucine Vuitton, Nicolas Mathieu, Laurent Peyrin Biroulet, Cyrielle Gilletta, Matthieu Allez, Stephanie Viennot, Caroline Trang-Poisson, David Laharie, Aurélien Amiot, null null
Determinants of IBD-related disability: a cross-sectional survey from the GETAID. Alimentary pharmacology & therapeutics 53 (10) (2021)
Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin Biroulet
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 81 (16) (2021)
Silvia D'Alessio, Federica Ungaro, Daniele Noviello, Sara Lovisa, Laurent Peyrin Biroulet, Silvio Danese
Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nature reviews. Gastroenterology & hepatology (2021)
Mathieu Uzzan, Clément Bresteau, David Laharie, Carmen Stefanescu, Christophe Bellanger, Franck Carbonnel, Mélanie Serrero, Stéphanie Viennot, Maria Nachury, Aurélien Amiot, Romain Altwegg, Laurence Picon, Stéphane Nahon, Lucine Vuitton, Philippe Ah Soune, Julien Kirchgesner, Laurent Peyrin Biroulet, Yoram Bouhnik, null null
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. Alimentary pharmacology & therapeutics 54 (3) (2021)
Bénédicte Caron, William J Sandborn, Stefan Schreiber, Remo Panaccione, Marjorie Costa Argollo, Laurent Peyrin Biroulet
Drug development for ulcerative proctitis: current concepts. Gut 70 (7) (2021)
Ferdinando D'Amico, Christian Rabaud, Laurent Peyrin Biroulet, Silvio Danese
SARS-CoV-2 vaccination in IBD: more pros than cons. Nature reviews. Gastroenterology & hepatology 18 (4) (2021)
Mariangela Allocca, Vincenzo Craviotto, Cecilia Dell'Avalle, Federica Furfaro, Alessandra Zilli, Ferdinando D'Amico, Stefanos Bonovas, Laurent Peyrin Biroulet, Gionata Fiorino, Silvio Danese
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. Alimentary pharmacology & therapeutics (2021)
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, Amélie Biron, David Laharie, Melanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stephane Nancey, Jean-Marc Gornet, Stephane Nahon, Guillaume Bouguen, Stephanie Viennot, Maria Nachury, Aurélien Amiot
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Alimentary pharmacology & therapeutics 54 (7) (2021)
François Avila, Bénédicte Caron, Gabriela Hossu, Khalid Ambarki, Stephan Kannengiesser, Freddy Odille, Jacques Felblinger, Silvio Danese, Myriam Choukour, Valérie Laurent, Laurent Peyrin Biroulet
Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study. Digestive diseases and sciences (2021)
Pablo A Olivera, Stéphane Zuily, Paulo Gustavo Kotze, Veronique Regnault, Sameer Al Awadhi, Peter Bossuyt, Richard B Gearry, Subrata Ghosh, Taku Kobayashi, Patrick Lacolley, Edouard Louis, Fernando Magro, William K K Wu, Alfredo Papa, Timothy Raine, Fabio V Teixeira, David T Rubin, Silvio Danese, Laurent Peyrin Biroulet
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology 18 (12) (2021)
Ahmed Almradi, Christopher Ma, Geert R D'Haens, William J Sandborn, Claire E Parker, Leonardo Guizzetti, Paula Borralho Nunes, Gert De Hertogh, Roger M Feakins, Reena Khanna, Gregory Y Lauwers, Aart Mookhoek, Reetesh K Pai, Laurent Peyrin Biroulet, Robert Riddell, Christophe Rosty, David F Schaeffer, Mark A Valasek, Siddharth Singh, Eileen Crowley, Brian G Feagan, Vipul Jairath, Rish K Pai
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Alimentary pharmacology & therapeutics 53 (7) (2021)
Bénédicte Caron, Elise Neuville, Laurent Peyrin Biroulet
Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey. Digestive diseases and sciences (2021)
Daniele Piovani, Silvio Danese, Laurent Peyrin Biroulet, Georgios K Nikolopoulos, Stefanos Bonovas
Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (9) (2020)
Silvio Danese, Bruce E Sands, William K K Wu, Laurent Peyrin Biroulet
The day after COVID-19 in IBD: how to go back to 'normal'. Nature reviews. Gastroenterology & hepatology 17 (8) (2020)
Sébastien Daude, Thomas Remen, Thomas Chateau, Silvio Danese, Isabelle Gastin, Cédric Baumann, Jean Louis Gueant, Laurent Peyrin Biroulet
Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (11) (2020)
Lieven Pouillon, Simon P L Travis, Peter Bossuyt, Silvio Danese, Laurent Peyrin Biroulet
Head-to-head trials in inflammatory bowel disease: past, present and future. Nature reviews. Gastroenterology & hepatology 17 (6) (2020)
Xavier Roblin, Nicolas Williet, Gilles Boschetti, Jean-Marc Phelip, Emilie Del Tedesco, Anne-Emmanuelle Berger, Philippe Vedrines, Gerard Duru, Laurent Peyrin Biroulet, Stéphane Nancey, Bernard Flourie, Stephane Paul
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut 69 (7) (2020)
Thomas Greuter, Florian Rieder, Torsten Kucharzik, Laurent Peyrin Biroulet, Alain M Schoepfer, David T Rubin, Stephan R Vavricka
Emerging treatment options for extraintestinal manifestations in IBD. Gut 70 (4) (2020)
Doriane Broussard, Pauline Riviere, Joelle Bonnet, Ginette Fotsing, Aurélien Amiot, Laurent Peyrin Biroulet, Sylvie Rajca, Anthony Buisson, Cyrielle Gilleta, Anne-Laure Pelletier, Melanie Serrero, Guillaume Bouguen, Romain Altwegg, Xavier Hebuterne, Stephane Nancey, Mathurin Fumery, Guillaume Cadiot, Stephane Nahon, Jean-Francois Rahier, Jean-Marc Gornet, Veronique Vendrely, David Laharie, null null
Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. Alimentary pharmacology & therapeutics 53 (3) (2020)
Sébastien Daude, Isabelle Gastin, Laurent Peyrin Biroulet
Editorial: diagnostic precision of iron deficiency in inflammatory bowel disease. Authors' reply. Alimentary pharmacology & therapeutics 52 (2) (2020)
Marianne Hupé, Pauline Riviere, Stephane Nancey, Xavier Roblin, Romain Altwegg, Jerome Filippi, Mathurin Fumery, Guillaume Bouguen, Laurent Peyrin Biroulet, Arnaud Bourreille, Ludovic Caillo, Mireille Simon, Felix Goutorbe, David Laharie
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Alimentary pharmacology & therapeutics 51 (9) (2020)
Ferdinando D'Amico, Stefanos Bonovas, Silvio Danese, Laurent Peyrin Biroulet
Review article: faecal calprotectin and histologic remission in ulcerative colitis. Alimentary pharmacology & therapeutics 51 (7) (2020)
Constance Chapuis-Biron, Anne Bourrier, Maria Nachury, Stéphane Nancey, Yoram Bouhnik, Mélanie Serrero, Laura Armengol-Debeir, Anthony Buisson, My-Linh Tran-Minh, Camille Zallot, Mathurin Fumery, Guillaume Bouguen, Vered Abitbol, Stéphanie Viennot, Elise Chanteloup, Sylvie Rajca, Nina Dib, Anne-Laure Parmentier, Laurent Peyrin Biroulet, Lucine Vuitton, null null
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Alimentary pharmacology & therapeutics 51 (7) (2020)
Marjorie Costa Argollo, Elmer Schabel, Mark Andrew Ainsworth, Laurent Peyrin Biroulet
Challenges and opportunities for IBD drug development: from early stage to regulatory approval. Gut 69 (7) (2020)
Daniele Piovani, Claudia Pansieri, Laurent Peyrin Biroulet, Silvio Danese, Stefanos Bonovas
Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. Alimentary pharmacology & therapeutics 53 (6) (2020)
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, Guillaume Cadiot, David Laharie, Melanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stephane Nancey, Jean-Marc Gornet, Stephane Nahon, Guillaume Bouguen, Stephanie Viennot, Benjamin Pariente, Mathurin Fumery, null null
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Alimentary pharmacology & therapeutics 51 (11) (2020)
Federica Furfaro, Lucine Vuitton, Gionata Fiorino, Stephane Koch, Mariangela Allocca, Daniela Gilardi, Alessandra Zilli, Ferdinando D'Amico, Simona Radice, Jean-Baptiste Chevaux, Marion Schaefer, Stanislas Chaussade, Silvio Danese, Laurent Peyrin Biroulet
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nature reviews. Gastroenterology & hepatology 17 (8) (2020)
Parambir S Dulai, Aurelien Amiot, Laurent Peyrin Biroulet, Vipul Jairath, Melanie Serrero, Jerome Filippi, Siddharth Singh, Benjamin Pariente, Edward V Loftus, Xavier Roblin, Sunanda Kane, Anthony Buisson, Corey A Siegel, Yoram Bouhnik, William J Sandborn, Karen Lasch, Maria Rosario, Brian G Feagan, Daniela Bojic, Caroline Trang-Poisson, Bo Shen, Romain Altwegg, Bruce E Sands, Jean Frederic Colombel, Franck Carbonnel, null null
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Alimentary pharmacology & therapeutics 51 (5) (2019)
Lieven Pouillon, Silvio Danese, Ailsa Hart, Gionata Fiorino, Marjorie Argollo, Carlo Selmi, Carmelo Carlo-Stella, Damien Loeuille, Antonio Costanzo, Anthony Lopez, Elena Vegni, Simona Radice, Daniela Gilardi, Marie Socha, Maria Fazio, Marien González-Lorenzo, Stefanos Bonovas, Fernando Magro, Laurent Peyrin Biroulet
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Alimentary pharmacology & therapeutics 49 (9) (2019)
Aurélien Amiot, Melanie Serrero, Laurent Peyrin Biroulet, Jerome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaud Vaysse, Anne Bourrier, Stephane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Jacques Moreau, Lucine Vuitton, Stephanie Viennot, Guillaume Bouguen, Vered Abitbol, Mathurin Fumery, Charlotte Gagniere, Yoram Bouhnik, null null
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary pharmacology & therapeutics 50 (1) (2019)
Parambir S Dulai, Siddharth Singh, Vipul Jairath, Christopher Ma, Neeraj Narula, Niels Vande Casteele, Laurent Peyrin Biroulet, Severine Vermeire, Geert D'Haens, Brian G Feagan, William J Sandborn
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Alimentary pharmacology & therapeutics 51 (4) (2019)
Stefanos Bonovas, T Lytras, G Nikolopoulos, Laurent Peyrin Biroulet, Silvio Danese
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply. Alimentary pharmacology & therapeutics 47 (4) (2019)
Daniele Piovani, Silvio Danese, Laurent Peyrin Biroulet, Stefanos Bonovas
Inflammatory bowel disease: estimates from the global burden of disease 2017 study. Alimentary pharmacology & therapeutics 51 (2) (2019)
L Pouillon, M Allocca, Laurent Peyrin Biroulet
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Alimentary pharmacology & therapeutics 48 (5) (2019)
P Wils, Y Bouhnik, Pierre Michetti, B Flourie, H Brixi, A Bourrier, M Allez, B Duclos, M Serrero, Anthony Buisson, Aurélien Amiot, M Fumery, Xavier Roblin, Laurent Peyrin Biroulet, J Filippi, Guillaume Bouguen, V Abitbol, B Coffin, M Simon, David Laharie, Benjamin Pariente, null null
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Alimentary pharmacology & therapeutics 47 (5) (2018)
Julien Sitte, Emilia Frentiu, Cédric Baumann, Hélène Rousseau, Thierry May, Jean-Pierre Bronowicki, Laurent Peyrin Biroulet, Anthony Lopez
Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. Alimentary pharmacology & therapeutics 49 (1) (2018)
W Yacoub, N Williet, L Pouillon, T Di-Bernado, M De Carvalho Bittencourt, S Nancey, Anthony Lopez, Stephane Paul, C Zallot, Xavier Roblin, Laurent Peyrin Biroulet
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Alimentary pharmacology & therapeutics 47 (7) (2018)
Pablo Andres Olivera, W J Sandborn, J Panés, C Baumann, G D'Haens, S Vermeire, Silvio Danese, Laurent Peyrin Biroulet
Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Alimentary pharmacology & therapeutics 47 (6) (2018)
S-C Sacleux, H Sarter, M Fumery, C Charpentier, N Guillon-Dellac, H Coevoet, Benjamin Pariente, Laurent Peyrin Biroulet, C Gower-Rousseau, G Savoye, null null
Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. Alimentary pharmacology & therapeutics 47 (12) (2018)
Guillaume Le Baut, Laurent Peyrin Biroulet, Guillaume Bouguen, Jean-Marc Gornet, Carmen Stefanescu, Aurélien Amiot, David Laharie, Romain Altwegg, Mathurin Fumery, Caroline Trang-Poisson, Lucine Vuitton, Marion Simon, Cyrielle Gilletta de Saint Joseph, Stéphane Nahon, Ludovic Caillo, Emilie Del Tedesco, Laurianne Plastaras, Alexandre Aubourg, Guillaume Pineton de Chambrun, Philippe Seksik, Stéphanie Viennot
Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary pharmacology & therapeutics 48 (8) (2018)
Laurent Peyrin Biroulet, Anthony Lopez, J R Fraser Cummings, Axel U Dignass, Trond Espen Detlie, Silvio Danese
Review article: treating-to-target for inflammatory bowel disease-associated anaemia. Alimentary pharmacology & therapeutics 48 (6) (2018)
Bobby Lo, M V Prosberg, L L Gluud, Webber Pak Wo Chan, R W Leong, E van der List, M van der Have, H Sarter, C Gower-Rousseau, Laurent Peyrin Biroulet, I Vind, Burisch J
Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Alimentary pharmacology & therapeutics 47 (1) (2017)
Stefanos Bonovas, T Lytras, G Nikolopoulos, Laurent Peyrin Biroulet, Silvio Danese
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Alimentary pharmacology & therapeutics 47 (4) (2017)
S Tadbiri, Laurent Peyrin Biroulet, M Serrero, J Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, C Stefanescu, C Trang-Poisson, R Altwegg, P Marteau, T Vaysse, A Bourrier, S Nancey, D Laharie, M Allez, G Savoye, C Gilletta, C Gagniere, L Vuitton, S Viennot, A Aubourg, A-L Pelletier, G Bouguen, V Abitbol, M Fumery, P Claudepierre, Y Bouhnik, Aurélien Amiot, null null
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Alimentary pharmacology & therapeutics 47 (4) (2017)
C Gouynou, Laurent Peyrin Biroulet
Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients. Alimentary pharmacology & therapeutics 46 (10) (2017)

Laurent Peyrin Biroulet.css-eqlu8i{font-size:small;padding-left:4px;} (L Peyrin-Biroulet, Laurent Peyrin-Biroulet)

Publication Activity (10 Years)

Top Topics

Top Venues

Laurent Peyrin Biroulet (L Peyrin-Biroulet, Laurent Peyrin-Biroulet)